Dyne Therapeutics Statistics
Total Valuation
DYN has a market cap or net worth of $3.46 billion. The enterprise value is $2.66 billion.
Important Dates
The next estimated earnings date is Monday, July 27, 2026, after market close.
| Earnings Date | Jul 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DYN has 165.31 million shares outstanding. The number of shares has increased by 40.32% in one year.
| Current Share Class | 165.31M |
| Shares Outstanding | 165.31M |
| Shares Change (YoY) | +40.32% |
| Shares Change (QoQ) | +11.80% |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 113.30% |
| Float | 164.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 937.61 |
| PB Ratio | 4.00 |
| P/TBV Ratio | 4.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.92, with a Debt / Equity ratio of 0.19.
| Current Ratio | 19.92 |
| Quick Ratio | 18.97 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.32 |
Financial Efficiency
Return on equity (ROE) is -58.89% and return on invested capital (ROIC) is -34.12%.
| Return on Equity (ROE) | -58.89% |
| Return on Assets (ROA) | -32.70% |
| Return on Invested Capital (ROIC) | -34.12% |
| Return on Capital Employed (ROCE) | -45.79% |
| Weighted Average Cost of Capital (WACC) | 9.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.72M |
| Employee Count | 263 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +100.96% in the last 52 weeks. The beta is 1.08, so DYN's price volatility has been similar to the market average.
| Beta (5Y) | 1.08 |
| 52-Week Price Change | +100.96% |
| 50-Day Moving Average | 18.41 |
| 200-Day Moving Average | 17.85 |
| Relative Strength Index (RSI) | 63.70 |
| Average Volume (20 Days) | 2,144,034 |
Short Selling Information
The latest short interest is 22.28 million, so 13.47% of the outstanding shares have been sold short.
| Short Interest | 22.28M |
| Short Previous Month | 20.98M |
| Short % of Shares Out | 13.47% |
| Short % of Float | 13.52% |
| Short Ratio (days to cover) | 16.05 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -471.09M |
| Pretax Income | -451.71M |
| Net Income | -451.71M |
| EBITDA | -468.99M |
| EBIT | -471.09M |
| Earnings Per Share (EPS) | -$3.18 |
Full Income StatementBalance Sheet
The company has $972.16 million in cash and $168.68 million in debt, giving a net cash position of $803.48 million or $4.86 per share.
| Cash & Cash Equivalents | 972.16M |
| Total Debt | 168.68M |
| Net Cash | 803.48M |
| Net Cash Per Share | $4.86 |
| Equity (Book Value) | 865.06M |
| Book Value Per Share | 5.24 |
| Working Capital | 969.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$442.24 million and capital expenditures -$19.95 million, giving a free cash flow of -$462.19 million.
| Operating Cash Flow | -442.24M |
| Capital Expenditures | -19.95M |
| Depreciation & Amortization | 2.10M |
| Net Borrowing | 154.46M |
| Free Cash Flow | -462.19M |
| FCF Per Share | -$2.80 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |